FAS Wealth Partners’s AbbVie ABBV Stock Holding History

FAS Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	–	–	379

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FAS Wealth Partners's ABBV Position: Q2 2026 in Review

FAS Wealth Partners increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $440K and bringing the position to 32,676 shares worth $8.22M. The position accounts for 0.43% of the portfolio, ranked #53.

FAS Wealth Partners first reported a position in ABBV in Q2 2017 and has held it in 35 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

FAS Wealth Partners held 32,676 shares of AbbVie worth $8.22M as of Q2 2026.
FAS Wealth Partners bought 2,047 AbbVie shares in Q2 2026, an estimated $440K.
AbbVie made up 0.43% of FAS Wealth Partners's portfolio in Q2 2026, its #53 holding.
FAS Wealth Partners first reported a position in AbbVie in Q2 2017 and has held it in 35 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on FAS Wealth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.